Search
COPD Paid Clinical Trials in Oklahoma
A listing of 4 COPD clinical trials in Oklahoma actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
The state of Oklahoma currently has 4 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Oklahoma City, Tulsa, Norman and Edmond.
Featured Trial
Evaluating an Investigational Drug in Adults with Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
The main goals of this study are to assess the safety and immune response of an investigational medication treatment in adults with COPD who are not currently receiving Inhaled Corticosteroid (ICS) and are at a high risk of heart and lung-related outcomes. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Chronic obstructive pulmonary disease (COPD)
All Conditions
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Investigational Combined COVID-19 and Influenza Vaccine
Recruiting
This study aims to evaluate the safety, immune response, and tolerability of an investigational vaccine designed to protect against both COVID-19 and seasonal influenza in adults aged 18 to 64 years. Participants will be randomly assigned to receive the investigational vaccine or a currently available vaccine. The study involves a single vaccination followed by monitoring over several months. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
Interested in vaccine studies
All Conditions
Healthy
Preventative Trials
Featured Trial
Investigational Stomach Flu Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Interested in vaccine studies
All Conditions
Preventative Trials
Healthy
Age 60+
Featured Trial
Healthy Volunteer Oral COVID-19 Preventative Drug
Recruiting
The main objectives of this study are to assess the safety, effectiveness, and immune response of an investigational oral preventative drug (oral vaccination) in preventing COVID-19 and its symptoms. Participants will be randomly assigned to receive the investigational oral vaccine or a currently available market COVID-19 vaccine. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Preventative Trials
Healthy
All Conditions
Interested in vaccine studies
Healthy Volunteers
Featured Trial
COPD Clinical Research Study
Recruiting
Living with COPD? We are transforming health by bringing clinical trials to you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Conditions:
COPD
Chronic Obstructive Pulmonary Disease
Pulmonary Disease
Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Tulsa, Oklahoma
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/06/2025
Locations: OK Clinical Research, Edmond, Oklahoma +1 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
11/27/2024
Locations: Research Site, Oklahoma City, Oklahoma +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2024
Locations: Research Site, Norman, Oklahoma +2 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
1 - 4 of 4